Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12381790 | 0.78 | MAPT (0.36) | KMT2AMAPTNOS3NOS1NOS2 | |
| SCHEMBL7905602 | 0.76 | BRD4 (0.47) | MAPK1MAPTPLA2G7BRD4PER2 | |
| SCHEMBL18883352 | 0.76 | BRD4 (0.47) | MAPK1MAPTPLA2G7BRD4PER2 | |
| SCHEMBL18821181 | 0.76 | BRD4 (0.47) | MAPK1MAPTPLA2G7BRD4PER2 | |
| SCHEMBL23102801 | 0.73 | MAPK1 (0.38) | MAPK1BRD4 | |
| SCHEMBL11989033 | 0.73 | MAPK1 (0.38) | MAPK1BRD4 | |
| SCHEMBL23425847 | 0.73 | MAPK1 (0.38) | MAPK1BRD4 | |
| SCHEMBL1089769 | 0.73 | — | — | |
| SCHEMBL19711769 | 0.73 | KMT2A (0.40) | TSHRKMT2AMAPK1CYP19A1MAPT | |
| SCHEMBL21962885 | 0.71 | TSHR (0.41) | TSHRKMT2AMAPK1CYP19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235880-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-8835693-B2 | Migrastatin analogs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140011844-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-01-09 | — | — | US | disclosed |
| US-8324284-B2 | Migrastatin analogs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-12-04 | — | — | US | disclosed |
| US-8314135-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110281916-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-7192980-B2 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | TSHR 4687/4885KMT2A 2957/4885MAPK1 2698/4885 |
| US-20110281916-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | KDR, HMGCR, LPAR3 | TSHR 994/4885KMT2A 2284/4885MAPK1 3044/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | TSHR 4732/4885KMT2A 2241/4885MAPK1 3662/4885 |
| US-20140011844-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | KDR, HMGCR, LPAR3 | TSHR 994/4885KMT2A 2284/4885MAPK1 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.